A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602)
about
Interest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer VaccineVaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges.Peptide-based vaccines for cancer therapyCancer vaccinesSystematic review of the use of granulocyte-macrophage colony-stimulating factor in patients with advanced melanomaAdjuvants for peptide-based cancer vaccinesSafety and tolerability evaluation of the use of Montanide ISA™51 as vaccine adjuvant: A systematic reviewLong-term outcomes of helper peptide vaccination for metastatic melanoma.Vaccination with Melanoma Helper Peptides Induces Antibody Responses Associated with Improved Overall Survival.Inflammatory adverse events are associated with disease-free survival after vaccine therapy among patients with melanoma.Immunologic hierarchy, class II MHC promiscuity, and epitope spreading of a melanoma helper peptide vaccine.A melanoma helper peptide vaccine increases Th1 cytokine production by leukocytes in peripheral blood and immunized lymph nodesThe present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination?Generation of more effective cancer vaccinesEstablishment of HLA-DR4 transgenic mice for the identification of CD4+ T cell epitopes of tumor-associated antigensCharacterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy.Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients.Immunoprevalence and magnitude of HLA-DP4 versus HLA-DR-restricted spontaneous CD4(+) Th1 responses against telomerase in cancer patients.MHC class I antigen presentation and implications for developing a new generation of therapeutic vaccines.PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8⁺ T cells induced by melanoma vaccinesMulti-target chimaeric VLP as a therapeutic vaccine in a model of colorectal cancer.Vaccines targeting helper T cells for cancer immunotherapy.Current status and future prospects of peptide-based cancer vaccines.Peptide-Based Cancer Vaccine Strategies and Clinical Results.CD20 alternative splicing isoform generates immunogenic CD4 helper T epitopes.Combination strategies to enhance the potency of monocyte-derived dendritic cell-based cancer vaccines.Peptide vaccines in cancer-old concept revisited.Engineering of a self-adjuvanted iTEP-delivered CTL vaccine.Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.Unique depot formed by an oil based vaccine facilitates active antigen uptake and provides effective tumour control.Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy
P2860
Q26782583-E486B4EB-39D8-4858-9A63-B0764A4E54B8Q26796314-3664DA50-C194-4161-87DE-EB3C118002D6Q27022312-897BBEE1-2F34-4C52-8295-5F4544174C9FQ27024438-3AD7B2A2-813E-4271-93CF-E5182045104BQ28067023-E55E3C7F-B2B1-48E3-9A6A-E0F06B74105DQ28072236-FE31F094-F044-4DD1-842A-D4B36D9E9904Q28084805-5807768D-A3CB-468A-AF4A-20D2580DA0EEQ30278874-F2035758-8AF9-478F-89F2-92F7B55DE8E8Q30299957-FB5C919C-4ED1-4DE4-8370-9050768BDF34Q30370026-AE8DFD2C-CD7C-403E-AB23-23D8492BDB0DQ30371547-DDB7883A-C785-4F7E-B7E2-48A9EFA8EF86Q30411269-B11D53C6-00B4-48FE-9391-B5EEFCB76E2DQ30425111-1300BB9D-D724-49AA-ADA3-502B51EED44BQ34169981-C78C9857-55E8-4F3C-B86F-EA304A747E63Q35081098-E8CD6F46-7079-4751-9BEC-68FE02652DDAQ35227810-00A19216-FE2F-40A3-AC68-F44FFF79B96EQ37012707-E7C3F47C-64A1-4BDA-AD72-9A5E04968433Q37012876-83366F7F-64E0-47E7-8F56-70ACA4968981Q37709626-C8CE7DED-080B-426D-BE02-08C104BC7A9AQ38264346-BB2554A6-C589-484C-9AEF-770BF1A6F753Q38621219-9D5EB603-F9A0-4700-9571-70A0433E8A01Q38649958-ED9BA0B1-E183-49B5-A138-99003E1E0222Q38780728-70A4F36C-1F1F-4701-8316-621A25351655Q38807849-8B17B9D6-CFE5-4502-BACB-2805822BAB02Q38935082-FE0BA6C2-2513-47FC-803A-0546AE81419EQ38948897-188FB670-9FED-4F1E-ADD6-051C9F736068Q39035351-8D0A6225-BC99-4017-8BE8-5D106A4D57CCQ40248942-CDAAFD22-F798-48D0-BFDA-6FC0F29FBE84Q43147493-7EB3E5CC-8F78-4B5B-B1AB-8F766979EB79Q47699178-5B11B735-288B-46F2-94D6-E06AF3966304Q56892924-43CF42C6-06BB-4629-91E8-CEB57A693F1B
P2860
A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602)
description
2013 nî lūn-bûn
@nan
2013 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
A randomized phase II trial of ...... th metastatic melanoma (E1602)
@ast
A randomized phase II trial of ...... th metastatic melanoma (E1602)
@en
type
label
A randomized phase II trial of ...... th metastatic melanoma (E1602)
@ast
A randomized phase II trial of ...... th metastatic melanoma (E1602)
@en
prefLabel
A randomized phase II trial of ...... th metastatic melanoma (E1602)
@ast
A randomized phase II trial of ...... th metastatic melanoma (E1602)
@en
P2093
P2860
P50
P1476
A randomized phase II trial of ...... th metastatic melanoma (E1602)
@en
P2093
Fengmin Zhao
John M Kirkwood
Philip D Leming
Sandra Lee
Theresa L Whiteside
Walter C Olson
P2860
P304
P356
10.1158/1078-0432.CCR-13-0002
P407
P577
2013-05-07T00:00:00Z